Another infusion option for axSpA! INVIGORATE-1: Phase 3 RCT of IV Secukinumab in axSpA Efficacious - ASAS40 response s
Tweet Content
Another infusion option for axSpA!
INVIGORATE-1: Phase 3 RCT of IV Secukinumab in axSpA
Efficacious - ASAS40 response sustained thru 52 weeks
Safety profile similar to subq version
@RheumNow #ACR23 Abs#2545 https://t.co/biC8p3p6dl
Show on Archive Page
On
Display in Search Results
On
PDQ
Off